Robert Millman

Robert Millman brings to MPM 20 years of experience in creating and managing intellectual property and patent estates for biotechnology and drug discovery and development companies. Prior to joining MPM Capital, he was the Chief IP Counsel for Alnylam Pharmaceuticals Inc., where he developed the leading intellectual property portfolio in RNAi therapeutics. Prior to Alnylam, for three years he served as the Chief IP Counsel at Infinity Pharmaceuticals, Inc., a company focused on small molecule discovery. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he developed and implemented an IP protection plan during the race to sequence the human genome. Mr. Millman has previously served as Patent Counsel at Millennium Pharmaceuticals, Inc., and earlier in his career; he held an associate position at Morrison and Foerster LLP and a patent agent/specialist position at Sterne, Kessler Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.